Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEOOTCMKTS:NWBONASDAQ:NXTCNASDAQ:TRVNNASDAQ:UROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.19+0.6%$7.37$2.83▼$9.01$87.25M1.49432,179 shs1.10 million shsNWBONorthwest Biotherapeutics$0.48+4.4%$0.53$0.40▼$1.09$554.07M-0.681.47 million shs1.10 million shsNXTCNextCure$1.29-10.4%$1.74$0.98▼$2.57$40.18M0.4199,986 shs156,328 shsTRVNTrevena$0.41+7.9%$0.49$0.30▼$3.28$6.98M1.1381,852 shs114,896 shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.63%-57.64%-56.66%-31.98%-0.31%NWBONorthwest Biotherapeutics+3.67%-6.47%-10.17%-20.10%-3.64%NXTCNextCure-10.42%-17.83%-34.52%+1.57%-13.42%TRVNTrevena+7.35%+11.75%-7.74%-35.72%-34.14%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.6408 of 5 stars3.51.00.04.51.61.70.6NWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.3217 of 5 stars3.55.00.04.60.01.71.3TRVNTrevena2.5549 of 5 stars3.55.00.00.02.50.00.6UROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.001,028.53% UpsideNWBONorthwest BiotherapeuticsN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00365.12% UpsideTRVNTrevena3.00Buy$9.002,100.49% UpsideUROVUrovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest NWBO, TRVN, NXTC, ABEO, and UROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.004/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M24.93N/AN/A$0.60 per share5.32NWBONorthwest Biotherapeutics$1.93M297.63N/AN/A($0.06) per share-7.95NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ATRVNTrevena$3.12M2.40N/AN/A($0.44) per share-0.93UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)NWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)TRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest NWBO, TRVN, NXTC, ABEO, and UROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023TRVNTrevenaN/A-$1.06-$1.06-$1.06$0.09 million($0.08) million3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15NWBONorthwest BiotherapeuticsN/A0.090.09NXTCNextCureN/A16.3816.38TRVNTrevena8.354.664.66UROVUrovant SciencesN/A2.912.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%NWBONorthwest Biotherapeutics0.04%NXTCNextCure42.65%TRVNTrevena13.56%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%NWBONorthwest Biotherapeutics9.40%NXTCNextCure11.90%TRVNTrevena2.40%UROVUrovant Sciences2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableNWBONorthwest Biotherapeutics251.20 billion1.09 billionNot OptionableNXTCNextCure8227.90 million24.58 millionOptionableTRVNTrevena2318.32 million17.88 millionOptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableNWBO, TRVN, NXTC, ABEO, and UROV HeadlinesSourceHeadlineOC Drugmakers Cut Headcounts, Close Officesocbj.com - April 22 at 7:23 PMA2 Bio’s new CEO aims to grow platformpacbiztimes.com - April 8 at 6:15 AMC-Suite Shuffle: A2 Bio, Bayer, BioNTech and Morebiospace.com - March 27 at 2:46 AMA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMHEALTH BEHAVIOR AND NUTRITION SCIENCESudel.edu - February 17 at 2:30 PMBulletin Science and Security Boardthebulletin.org - February 15 at 3:32 PMSecretary-General’s Guidance Note on Behavioural Scienceun.org - February 5 at 9:35 AMMarine Sciences & Technologyuml.edu - January 7 at 12:52 PMThe 7 Best Science Kits for Kids and Teenspopularmechanics.com - December 22 at 12:32 AMCareers in Computer Sciencemccormick.northwestern.edu - December 11 at 10:18 AMPhD in Information Sciencedrexel.edu - December 8 at 10:01 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMCore Requirements & Coursesbc.edu - December 1 at 1:25 PMInspiring Women in Sciencenature.com - November 28 at 10:11 AMDevelop your own cognitive toolkit.miamioh.edu - November 17 at 9:55 AMBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightmedgadget.com - November 16 at 8:17 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis Cmedpagetoday.com - September 26 at 3:23 PMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMClinical and Translational Science Institutebuffalo.edu - September 8 at 9:36 PMMDxHealth CEO Bullish After Q2 Revenue Boostocbj.com - September 5 at 8:49 PMWindmill Model Science Projecteducation.com - August 15 at 1:51 AMTop Science Newssciencedaily.com - August 10 at 1:52 PMAbout This Sitesciencedaily.com - August 5 at 4:13 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.